T helper-1 activation via interleukin-16 is a key phenomenon in the acute phase of severe, first-episode major depressive disorder and suicidal behaviors

Background: Immune-inflammatory pathways in major depressive disorder are confined to the major dysmood disorder (MDMD) phenotype (Maes et al., 2022). No studies have addressed the immune profile of first episode MDMD (FE-MDMD). Methods: This study examines 48 cytokines/chemokines/growth factors, and classical M1, alternative M2, T helper (Th)-1, Th-2, and Th-17 phenotypes, immune-inflammatory response system (IRS), compensatory immunoregulatory system (CIRS), and neuro-immunotoxicity profiles in the acute phase of FE-MDMD (n=71) versus healthy controls (40). Results: FE-MDMD patients show significantly activated M1, M2, Th-1, IRS, CIRS, and neurotoxicity, but not Th-2 or Th-17, profiles compared to controls. FE-MDMD is accompanied by Th-1 polarization, while there are no changes in M1/M2 or IRS/CIRS ratios. The top single indicator of FE-MDMD was by far interleukin (IL)-16, followed at a distance by TRAIL, IL-2R, tumor necrosis factor (TNF)-{beta}. The severity of depression and anxiety was strongly associated with IRS (positively) and Th-2 (inversely) profiles, whereas suicidal behavior was associated with M1 activation. Around 56-60% of the variance in depression, anxiety, and suicidal behavior scores was explained by IL-16, platelet-derived growth factor (PDGF) (both positively), and IL-1 receptor antagonist (inversely). Increased neurotoxicity is mainly driven by IL-16, TNF-, TRAIL, IL-6 and chemokine (CCL2, CCL11, CXCL1, CXCL10) signaling. Antidepressant-treated patients show an increased IRS/CIRS ratio as compared with drug-naive FE-MDMD patients. Conclusions: FE-MDMD is accompanied by positive regulation of the IRS mainly driven by Th-1 polarization and T cell activation (via binding of IL-16 to CD4), and TNF, chemokine, and growth factor signaling.

[1]  M. Benros,et al.  Comparisons of 25 cerebrospinal fluid cytokines in a case–control study of 106 patients with recent-onset depression and 106 individually matched healthy subjects , 2023, Journal of Neuroinflammation.

[2]  Michael Maes,et al.  Reverse cholesterol transport and lipid peroxidation biomarkers in major depression and bipolar disorder: A systematic review and meta-analysis , 2023, Brain, Behavior, and Immunity.

[3]  K. Plaimas,et al.  Adverse childhood trauma and reoccurrence of illness impact the gut microbiome, which affects suicidal behaviors and the phenome of major depression: towards enterotypic-phenotypes , 2023, medRxiv.

[4]  H. Al-Hakeim,et al.  The physio-affective phenome of major depression is strongly associated with biomarkers of astroglial and neuronal projection toxicity which in turn are associated with peripheral inflammation, insulin resistance and lowered calcium , 2022, medRxiv.

[5]  G. Oxenkrug,et al.  The tryptophan catabolite or kynurenine pathway in major depressive and bipolar disorder: A systematic review and meta-analysis , 2022, medRxiv.

[6]  K. Plaimas,et al.  In Vitro Effects of Cannabidiol on Activated Immune–Inflammatory Pathways in Major Depressive Patients and Healthy Controls , 2022, Pharmaceuticals.

[7]  Michael Maes.  Precision Nomothetic Medicine in Depression Research: A New Depression Model, and New Endophenotype Classes and Pathway Phenotypes, and A Digital Self , 2022, Journal of personalized medicine.

[8]  M. Maes,et al.  Inflammation and nitro-oxidative stress in current suicidal attempts and current suicidal ideation: a systematic review and meta-analysis , 2021, Molecular Psychiatry.

[9]  Hui-Rong Jiang,et al.  Increased Levels of IL-16 in the Central Nervous System during Neuroinflammation Are Associated with Infiltrating Immune Cells and Resident Glial Cells , 2021, Biology.

[10]  Y. Liou,et al.  Interleukin-1 family and serotonin transporter in first-episode, drug-naive major depressive disorder: A pilot study. , 2021, Journal of psychiatric research.

[11]  M. Maes,et al.  Construction of a nitro-oxidative stress-driven, mechanistic model of mood disorders: a nomothetic network approach. , 2020, Nitric oxide : biology and chemistry.

[12]  M. Maes,et al.  Towards a new model and classification of mood disorders based on risk resilience, neuro-affective toxicity, staging, and phenome features using the nomothetic network psychiatry approach , 2020, Metabolic Brain Disease.

[13]  B. Penninx,et al.  Altered peripheral blood compounds in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis , 2020, Brain, Behavior, and Immunity.

[14]  M. Maes,et al.  Development of a Novel Staging Model for Affective Disorders Using Partial Least Squares Bootstrapping: Effects of Lipid-Associated Antioxidant Defenses and Neuro-Oxidative Stress , 2018, Molecular Neurobiology.

[15]  M. Maes,et al.  The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder , 2018, Molecular Neurobiology.

[16]  Marcin Siwek,et al.  Are there differences in lipid peroxidation and immune biomarkers between major depression and bipolar disorder: Effects of melancholia, atypical depression, severity of illness, episode number, suicidal ideation and prior suicide attempts , 2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[17]  B. Leuner,et al.  A survey of neuroimmune changes in pregnant and postpartum female rats , 2017, Brain, Behavior, and Immunity.

[18]  R. Cowan,et al.  Structure of a Potential Therapeutic Antibody Bound to Interleukin-16 (IL-16) , 2016, The Journal of Biological Chemistry.

[19]  J. Schwarz,et al.  An investigation into the effects of antenatal stressors on the postpartum neuroimmune profile and depressive-like behaviors , 2016, Behavioural Brain Research.

[20]  Michael Berk,et al.  Oxidative & nitrosative stress in depression: Why so much stress? , 2014, Neuroscience & Biobehavioral Reviews.

[21]  M. Inglot,et al.  Depression and neuroticism in patients with chronic hepatitis C: correlation with peripheral blood mononuclear cells activation. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[22]  M. Kubera,et al.  Activation of cell-mediated immunity in depression: Association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[23]  Barbara Stanley,et al.  The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. , 2011, The American journal of psychiatry.

[24]  M. Mathieu,et al.  Anti-inflammatory properties of desipramine and fluoxetine , 2007, Respiratory research.

[25]  E. Bosmans,et al.  Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis , 2001, European Neuropsychopharmacology.

[26]  R. Kurth,et al.  Interleukin‐16 stimulates the expression and production of pro‐inflammatory cytokines by human monocytes , 2000, Immunology.

[27]  E. Bosmans,et al.  Negative Immunoregulatory Effects of Antidepressants: Inhibition of Interferon-γ and Stimulation of Interleukin-10 Secretion , 1999, Neuropsychopharmacology.

[28]  L. Träskman-bendz,et al.  Increased soluble interleukin‐2 receptor concentrations in suicide attempters , 1993, Acta psychiatrica Scandinavica.

[29]  P. Cosyns,et al.  Significantly increased expression of T-cell activation markers (interleukin-2 and HLA-DR) in depression: Further evidence for an inflamatory process during that illness , 1993, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[30]  E. Bosmans,et al.  Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining , 1992, Psychological Medicine.

[31]  E. Bosmans,et al.  Depression‐related disturbances in mitogen‐induced lymphocyte responses and interleukin‐1β and soluble interleukin‐2 receptor production , 1991, Acta psychiatrica Scandinavica.

[32]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[33]  M. Hamilton.  The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.